

Evry, June 12, 2020,

Enalees complements its product line Astéria with a brand new rapid COVID-19 test kit for domestic cats

After the critical success in developing a rapid SARS-CoV-2 detection kit for human diagnosis as well as environmental surveillance in a joint effort with Bertin Technologies and C4Diagnostics, Enalees now refocuses on its expertise in animal health and launches a COVID-19 test kit for domestic cats, a point-of-care test that is deployed directly in vet clinics.

Having acquired the market leader status in molecular point-of-care tests of equine infectious diseases through its Epona product line that is used regularly by 25% of French vet clinics in only 18 months after its launch, Enalees now launches Astéria, its product line designated for diagnosis of feline and canine infectious diseases in March of 2020. Enabling veterinarians to diagnose infectious diseases rapidly, accurately, and directly on-site, the Astéria product line is now complemented by a COVID-19 test kit for domestic cats.

Capable of detecting the SARS-CoV-2 virus in less than 30 minutes on-site from a simple saliva sample, the Astéria COVID-19 test kit provides the solutions to several problems. :

- ▶ Prevention of animal abandonment by reassuring the pet owners of the health of their companion animals.
- ▶ Diminution of COVID-19 clusters by examining companion animals of infected pet owners before pet boarding and avoiding contamination of the host family or pet lodging facility.
- ▶ Management of COVID-19 crisis in the clinic in real-time by identifying the infected animals and alerting the pet owners to effectuate quarantine.

This test carries the same simplicity and performance as all the other tests in the Epona and Astéria product lines. The test kit includes a positive control which validates the quality of the saliva sample. The launch is scheduled in July in France, and will be available as well in United Kingdom, the Netherlands, Germany, and Austria, through respective distributors.

Laurent Thiery, president of Enalees states:



This test is not intended for infectious disease surveillance, but rather for the reassurance of pet owners and the management of disease clusters by health professionals. It is a tool that perfectly complements the human diagnosis and thus abides by the One Health principle.

About Enalees : Enalees is a French start-up created in 2015 at the site of Genopole in Evry, in the southern suburbs of Paris. Enalees develops, manufactures, and commercialises molecular point-of-care tests of infectious diseases affecting companion animals including horses, dogs, and cats. Their test kits diagnose infections such as equine influenza, Leptospirosis, and Lyme disease. These innovative tests are simple, rapid, and can be deployed directly on-site by veterinary practitioners during consultations. The first infectious equine disease test kits were launched in 2019 and have been used routinely by 25% of French clinics. Enalees has since commercialised test kits for cats and dogs, bringing the total number of kits to 15, all of which available throughout Europe and ready for launch in North America.

www.enalees.com

Contact Enalees

Laurent THIERY, PhD
CEO and Co-Founder
+33 (0) 6 32 512 519
laurent.thiery@enalees.com